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Abstract
Background: Major depression is one of the leading causes of disability worldwide, yet epidemiologic data are not
available for many countries, particularly low- to middle-income countries. In this paper, we present data on the
prevalence, impairment and demographic correlates of depression from 18 high and low- to middle-income
countries in the World Mental Health Survey Initiative.
Methods: Major depressive episodes (MDE) as defined by the Diagnostic and Statistical Manual of Mental Disorders,
fourth edition (DMS-IV) were evaluated in face-to-face interviews using the World Health Organization Composite
International Diagnostic Interview (CIDI). Data from 18 countries were analyzed in this report (n = 89,037). All
countries surveyed representative, population-based samples of adults.
Results: The average lifetime and 12-month prevalence estimates of DSM-IV MDE were 14.6% and 5.5% in the ten
high-income and 11.1% and 5.9% in the eight low- to middle-income countries. The average age of onset
ascertained retrospectively was 25.7 in the high-income and 24.0 in low- to middle-income countries. Functional
impairment was associated with recency of MDE. The female: male ratio was about 2:1. In high-income countries,
younger age was associated with higher 12-month prevalence; by contrast, in several low- to middle-income
countries, older age was associated with greater likelihood of MDE. The strongest demographic correlate in high-
income countries was being separated from a partner, and in low- to middle-income countries, was being
divorced or widowed.
Conclusions: MDE is a significant public-health concern across all regions of the world and is strongly linked to
social conditions. Future research is needed to investigate the combination of demographic risk factors that are
most strongly associated with MDE in the specific countries included in the WMH.
Background
Major depression is a serious, recurrent disorder linked
to diminished role functioning and quality of life, medi-
cal morbidity, and mortality [1,2]. The World Health
Organization ranks depression as the fourth leading
cause of disability worldwide [3], and projects that by
2020, it will be the second leading cause [4]. Although
direct information on the prevalence of depression does
not exist for most countries, the available data indicate
wide variability in the prevalence rates. Weissman et al.
[5] published the first cross-national comparison of
major depression as defined by the Diagnostic and Sta-
tistical Manual of Mental Disorders, third edition
(DSM-III) from 10 population-based surveys that used
the Diagnostic Interview Schedule (DIS) [6]. The life-
time prevalence ranged from 1.5% (Taiwan) to 19.0%
(Beirut), with the midpoints at 9.2% (West Germany)
and 9.6% (Edmonton, Canada). The 12-month preva-
lence ranged from 0.8% (Taiwan) to 5.8% (Christchurch,
New Zealand), with the midpoints at 3.0% (US) and
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4.5% (Paris). A subsequent cross-national comparison
[7] included 10 population-based studies that used the
World Health Organization (WHO) Composite Interna-
tional Diagnostic Interview (CIDI) for the revised third
edition and the fourth edition of the DSM (DSM-III-R)
and (DSM-IV) [8]. Consistent with the earlier report [5],
the lifetime rates ranged from 1.0% (Czech Republic) to
16.9% (US), with midpoints at 8.3% (Canada) and 9.0%
(Chile). The 12-month prevalence ranged from 0.3%
(Czech Republic) to 10% (USA), with midpoints at 4.5%
(Mexico) and 5.2% (West Germany). Most recently,
Moussavi et al. [9] summarized data on depressive epi-
sodes as defined by the International Classification of
Diseases, 10th revision (ICD-10) in participants in the
WHO World Health Survey used in 60 countries, noting
that the 1-year prevalence was 3.2% in participants with-
out comorbid physical disease, and 9.3% to 23.0% in
participants with chronic conditions.
The wide variability in lifetime and 12-month preva-
lence estimates of major depression is presumably due
to a combination of substantive (genetic vulnerability
and environmental risk factors) and measurement (cul-
tural differences in the acceptance and meaning of
items, and the psychometric properties of the instru-
ments) factors. Differences in study design might also be
involved. That is, apart from administering a common
interview schedule, the surveys were not designed as
replications with a standard protocol for translation,
interviewer training, sampling and quality control. More
recently, the WHO World Mental Health (WMH) Sur-
vey Initiative conducted a coordinated series of studies
using a common protocol and a common instrument,
the WHO CIDI, version 3.0 [10], to assess a set of
DSM-IV disorders in countries from every continent
[11]. The 12-month prevalence of DSM-IV major
depressive episode (MDE) in 18 countries ranged from
2.2% (Japan) to 10.4% (Brazil) [12]. The mid-point
across all countries was similar to that in previous sur-
veys (5%), as was the weighted average 12-month preva-
lence for the ten high-income (5.5%) and eight low- to
middle-income (5.9%) countries.
Almost all studies find that gender, age and marital sta-
tus are associated with depression. Women have a twofold
increased risk of MDE compared with men [13], people
who are separated or divorced have significantly higher
rates of depression than the currently married [5,7], and
the rate of depression generally goes down with age [5,7].
This evidence, however, comes primarily from studies
conducted in western countries. The sparse data available
from low- to middle-income countries suggest that the
age pattern is either not monotonic or that the association
is reversed, with depression increasing with age [12,14].
Other socioeconomic factors have less consistent relation-
ships with depression in different countries [7].
The current report presents data on the prevalence,
age of onset and sociodemographic correlates of MDE
in 18 countries participating in the WHO WMH Survey
Initiative. As noted earlier, each of the WMH surveys
used the CIDI for DSM-IV. The CIDI includes a series
of diagnostic stem questions to determine which diag-
noses are assessed. Unlike previous reports from the
WMH or previous surveys, our study used the screening
information for MDE in responses to these diagnostic
stem questions to conduct an examination of the
screen-positive percentages, and of the conditional life-
time and 12-month prevalence of MDE in respondents
who endorsed the diagnostic stem questions. This was
carried out to investigate the possibility that cross-
national differences in prevalence estimates of MDE are
due, at least in part, to differences across countries in
the optimal threshold of CIDI symptom scores for
detecting clinical cases. If such variation exists, we
would expect much smaller cross-national differences in
endorsement of diagnostic stem questions (which merely
ask respondents if they had episodes of several days of
being sad or depressed or losing interest in usual activ-
ities), than in diagnoses. If this were the case, we would
expect the largest cross-national differences in condi-
tional prevalence estimates of MDE to occur in screened
positives. If differential variation of this sort exists, it
would provide more reason than currently exists to sus-
pect that cross-national differences in optimal diagnostic
thresholds of the CIDI symptom scale lead to biased
estimates of cross-national differences in prevalence in
the WMH data.
A justification for this line of thinking comes from an
earlier cross-national WHO study of major depression
in primary-care patients, which found strong similarity
in the latent structure of depressive symptoms across 14
different countries in different parts of the world, but
also found that countries with the highest prevalence
estimates generally reported the lowest impairment
associated with depression [15]. The authors concluded
from these results that although cross-national differ-
ences in the estimated prevalence of depression cannot
be attributed to differences in the nature or validity of
the concept of a depressive episode, it is possible that
DSM criteria may define different levels of depression
severity in different countries. Our cross-national com-
parison of responses to diagnostic stem questions,
described in the previous paragraph, was designed to
shed some light on this possibility. In addition, we car-
ried out a parallel analysis of cross-national differences
in impairment associated with MDE.
Results are organized by distinguishing between coun-
tries classified by the World Bank [16] as low- or mid-
dle-income versus higher-income countries. This
distinction was made based on patterns both in the
Bromet et al. BMC Medicine 2011, 9:90
http://www.biomedcentral.com/1741-7015/9/90
Page 2 of 16
WMH surveys [10] and in other cross-national epide-
miologic surveys [7,9], which raise concerns that MDE
prevalence estimates might be artificially lower in low-
to middle- than higher-income countries due to metho-
dological differences of the types considered here.
Methods
Ethics
Procedures for human subject protection were approved
and monitored for compliance by the institutional
review boards of each local organization coordinating
the survey. Informed consent was obtained before begin-
ning interviews in all countries.
Sampling and procedure
The WMH surveys are a series of community-based stu-
dies conducted throughout the world [11]. This paper
included data on MDE from ten high-income countries
(Belgium, France, Germany, Israel, Italy, Japan, Nether-
lands, New Zealand, Spain, United States) and eight
low- to middle-income countries (Brazil (São Paulo),
Colombia, India (Pondicherry), China (Shenzhen), Leba-
non, Mexico, South Africa, Ukraine) based on World
Bank development criteria [16]. As noted in the intro-
duction, we distinguished results from low- to middle-
income versus higher-income countries based on the
suspicion that optimal thresholds for defining clinically
significant depression might be lower than the CIDI
thresholds in the former countries, resulting in underes-
timation of the prevalence of MDE in the CIDI in those
countries. The surveys involved either national house-
hold samples or representative samples of urban areas
(Table 1). Weights were used to adjust for differential
probabilities of selection into the study, and to match
the sample sociodemographic distributions with the
population distributions within each country. Sample
sizes ranged from 2,372 (the Netherlands) to 12,790
(New Zealand), giving a total of 89,037. The average
weighted response rate was 71.7% (Table 1).
The WMH interviews were administered face-to-face by
trained lay interviewers. To reduce respondent burden, the
interview was divided into two parts. All respondents
completed part I, which assessed a set of core mental dis-
orders, including MDE. Part II assessed additional disor-
ders and correlates, and was administered to all part I
respondents who met criteria for a part I disorder, plus a
probability subsample of other part I respondents. Part II
responses were weighted by the inverse of their probability
of selection into part II to adjust for differential selection.
Details about WMH survey methods and weighting proce-
dures are presented elsewhere [11,17].
Standardized procedures for interviewer training,
translation of study materials and quality control were
consistently used in each country [11].
Measures
MDE
Near the start of the interview, the CIDI includes three
screening questions about sadness/depressed mood, feel-
ings of discouragement, and loss of interest lasting sev-
eral days or longer. Respondents endorsing one or more
of these questions (screen-positives) were given the
remainder of the MDE module. DSM-IV MDE requires
the presence of five of nine cardinal symptoms that per-
sist for 2 weeks or longer, are present for most of the
day nearly every day, and cause significant distress or
impairment. These symptoms are depressed mood and
markedly diminished interest or pleasure (one of these
must be present to meet the criteria for diagnosis), and
clinically significant weight gain/loss or appetite distur-
bance, insomnia or hypersomnia, psychomotor agitation
or retardation, fatigue or loss of energy, feelings of
worthlessness or excessive guilt, diminished ability to
concentrate or think clearly, and recurrent thoughts of
death or suicide. MDE was defined for purposes of the
present report without organic exclusions and without
diagnostic hierarchy rules [12]. Clinical reappraisal stu-
dies conducted in several countries found good agree-
ment between diagnoses of MDE based on the CIDI
and independent diagnoses based on blinded reappraisal
interviews carried out by a clinician [18].
It is noteworthy that the CIDI interview translation,
back-translation and harmonization protocol required
culturally competent bilingual clinicians in the partici-
pating countries to review, modify and approve the key
phrases used to describe symptoms of all disorders
assessed in the survey [19]. That meant that the terms
used to describe core symptoms of depression (that is,
sadness, depression, loss of interest) were customized
when the original CIDI wording did not match the
terms used in the local settings. However, no attempt
was made to go beyond the DSM-IV criteria to develop
distinct criteria for depression-equivalents that might be
unique to specific countries. It is conceivable that the
latter kind of expansion would have led to a reduction
in cross-national variation in prevalence estimates. How-
ever, as noted in the introduction, previous research has
shown that the latent structure of the symptoms of
major depression is consistent across countries [15],
providing a principled basis for focusing on this criter-
ion set in our analysis.
Global impairment
A modified version of the WHO Disability Assessment
Schedule-II (WHO-DAS-II) was used to assess fre-
quency and intensity of restrictions in performing nor-
mal activities during the 30 days prior to the interview
[20]. The activity areas included the number of days the
person was unable to carry out their normal daily activ-
ities because of problems with physical or emotional
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Table 1 World Mental Health (WMH) Survey sample characteristics
Sample size
Country Surveya Sample characteristicsb Field
dates
Age
range
Part I Part
II
Part II and
age ≤ 44
yearsd
Response
ratec
I. High-income
Belgium ESEMeD Stratified multistage clustered probability sample of individuals
residing in households from the national register of Belgium
residents. NR
2001-
2
18+ 2419 1043 486 50.6
France ESEMeD Stratified multistage clustered sample of working telephone
numbers merged with a reverse directory (for listed numbers).
Initial recruitment was by telephone, with supplemental in-person
recruitment in households with listed numbers. NR
2001-
2
18+ 2894 1436 727 45.9
Germany ESEMeD Stratified multistage clustered probability sample of individuals
from community resident registries. NR
2002-
3
18+ 3555 1323 621 57.8
Israel NHS Stratified multistage clustered area probability sample of
individuals from a national resident register. NR
2002-
4
21+ 4859 4859 – 72.6
Italy ESEMeD Stratified multistage clustered probability sample of individuals
from municipality resident registries. NR
2001-
2
18+ 4712 1779 853 71.3
Japan WMHJ
2002-
2006
Unclustered two-stage probability sample of individuals residing
in households in nine metropolitan areas (Fukiage, Higashi-ichiki,
Ichiki, Kushikino, Nagasaki, Okayama, Sano, Tamano, Tendo
Tochigi)
2002-
6
20+ 3416 1305 425 59.2
Netherlands ESEMeD Stratified multistage clustered probability sample of individuals
residing in households that are listed in municipal postal
registries. NR
2002-
3
18+ 2372 1094 516 56.4
New
Zealande
NZMHS Stratified multistage clustered area probability sample of
household residents. NR
2004-
5
18+ 12790 7312 4119 73.3
Spain ESEMeD Stratified multistage clustered area probability sample of
household residents. NR
2001-
2
18+ 5473 2121 960 78.6
United
States
NCS-R Stratified multistage clustered area probability sample of
household residents. NR
2002-
3
18+ 9282 5692 3197 70.9
II. Low- to middle-income
Brazil São
Paulo
megacity
Stratified multistage clustered area probability sample of
household residents in the São Paulo metropolitan area, Brazil
2004-
7
18+ 5037 2942 – 77.7
Colombia NSMH Stratified multistage clustered area probability sample of
household residents in all urban areas of the country
(approximately 73% of the total national population)
2003 18-65 4426 2381 1731 87.7
India WMHI Stratified multistage clustered area probability sample of
household residents in Pondicherry region, India. NR
2003-
5
18+ 2992 1373 642 98.6
Lebanon LEBANON Stratified multistage clustered area probability sample of
household residents. NR
2002-
3
18+ 2857 1031 595 70.0
Mexico M-NCS Stratified multistage clustered area probability sample of
household residents in all urban areas of the country
(approximately 75% of the total national population)
2001-
2
18-65 5782 2362 1736 76.6
South
Africa
SASH Stratified multistage clustered area probability sample of
household residents. NR
2003-
4
18+ 4315 4315 – 87.1
Ukraine CMDPSD Stratified multistage clustered area probability sample of
household residents. NR
2002 18+ 4724 1719 540 78.3
PRC Shenzhen Stratified multistage clustered area probability sample of
household residents and temporary residents in the Shenzhen
area, China
2006-
7
18+ 7132 2475 1994 80.0
aESEMeD (The European Study Of The Epidemiology Of Mental Disorders); NHS (Israel National Health Survey); WMHJ 2002-2006 (World Mental Health Japan
Survey); NZMHS (New Zealand Mental Health Survey); NCS-R (The USA National Comorbidity Survey Replication); NSMH (The Colombian National Study of Mental
Health); WMHI (World Mental Health India); LEBANON (Lebanese Evaluation of the Burden of Ailments and Needs of the Nation); M-NCS (The Mexico National
Comorbidity Survey); SASH (South Africa Stress and Health Study); CMDPSD (Comorbid Mental Disorders during Periods of Social Disruption)
bMost WMH surveys are based on stratified multistage clustered area probability household samples in which samples of areas equivalent to counties or
municipalities in the USA were selected in the first stage, followed by one or more subsequent stages of geographic sampling (for example,, towns within
counties, blocks within towns, households within blocks) to arrive at a sample of households, in each of which a listing of household members was created, and
Bromet et al. BMC Medicine 2011, 9:90
http://www.biomedcentral.com/1741-7015/9/90
Page 4 of 16
health as well as various difficulties in role performance
during the days in role. WHO-DAS scores are coded in
the range 0 to 100, where 0 represents no impairment
and 100 total impairment. Reported levels of impair-
ment were low in all countries, with means in the range
1.0 to 5.5 in high-income countries and 1.1 to 4.8 in
low- to middle-income countries.
Demographic factors
We examined gender, age (18 to 34, 35 to 49, 50 to 64,
65+), current marital status (separated, divorced,
widowed, never married, currently married), living
arrangement (alone, with others but not spouse/partner,
with spouse/partner), income (low, low average, high
average, and high, which were based on country-specific
quartiles of gross household earnings in the past 12
months [21]) and education (low, low average, high
average or high, which were based on country-specific
quartiles that take into consideration the fact that distri-
butions of educational attainment vary widely between
countries [22]).
Statistical analysis
Cross-tabulations were used to estimate the absolute
and relative lifetime and 12-month prevalence of endor-
sing diagnostic stem questions and meeting DSM-IV/
CIDI criteria for a diagnosis of MDE. F-tests (linear
regression) were used to study differences in global
impairment by recency of MDE (past 30 days, past
month but not in the past 30 days, prior to the past
year, never). Logistic regression analysis was used to
examine sociodemographic correlates. Unadjusted odds
ratios and 95% confidence intervals are presented for
these associations. Because the data were weighted and
clustered, the Taylor series linearization method [23]
implemented in the SUDAAN software package [24]
was used to estimate design-based standard errors. Sta-
tistical significance was consistently evaluated using
two-sided tests, with P < 0.05 considered significant.
Results
Prevalence of MDE
On average, about half of the respondents in both high-
income (52.3%) and low- to middle-income (54.1%)
countries endorsed at least one depression diagnostic
stem question (screen-positive). (Table 2) However, the
screen-positive rate ranged widely, from < 30% in Japan
and Pondicherry (India) to ≥ 60% in France, New Zeal-
and, the USA, Brazil and Ukraine. The ratio of the high-
est to lowest screen-positive rates across countries was
3.3. On average, the estimated lifetime prevalence was
higher in high-income (14.6%) than low- to middle-
income (11.1%) countries (t = 5.7, P < 0.001). Indeed,
the four lowest lifetime prevalence estimates (< 10%)
were in low- to middle-income countries (India, Mexico,
China, South Africa). Conversely, with the exception of
Brazil, the highest rates (> 18%) were in four high-
income countries (France, the Netherlands, New Zeal-
and, the USA).
The percentage of the screen-positive respondents
who had lifetime MDE was also higher in high-income
(28.1%) than in low- to middle-income (19.8%) coun-
tries, although both the lowest and the highest percen-
tages were in low- to middle-income countries (12.0% in
China vs. 35.9% in India). The ratio of the highest to
lowest conditional prevalence scores in screened posi-
tives is 3.0. Among the high-income countries, these
conditional prevalence estimates were relatively low (<
25%) in Germany, Italy, Israel and Japan, and higher (>
30%) in the Netherlands and USA.
We previously reported that the pooled 12-month pre-
valence of MDE was similar in high-income (5.5%) and
low- to middle-income (5.9%) countries (t = 1.2, P =
0.25), with the specific estimates varying from 2.2%
(Japan) to 8.3% (USA) in high-income countries, and
from 3.8% (China) to 10.4% (Brazil) in low- to middle-
income countries [11]. In the group of screen-positive
respondents, the percentage with 12-month MDE was
also similar for high-income (10.6%) and low- to mid-
dle-income (10.5%) countries (Table 2). The lowest rate
was 6.7% (Italy) and the highest 18.0% (India). In 10
countries, these percentages were between 8 and 12%.
The ratio of the 12-month prevalence to lifetime preva-
lence is an indirect indicator of persistence. This ratio was
significantly lower on average in surveys carried out in
high-income (37.7%) than low- to middle-income (53.3%)
one or two people were selected from this listing to be interviewed. No substitution was allowed when the originally sampled household resident could not be
interviewed. These household samples were selected from Census area data in all countries other than France (for which telephone directories were used to
select households) and the Netherlands (for which postal registries were used to select households). Several WMH surveys (Belgium, Germany, Italy) used
municipal resident registries to select respondents without listing households. The Japanese sample is the only totally unclustered sample, with households
randomly selected in each of the four sample areas, and one random respondent selected in each sample household. Fourteen surveys are based on nationally
representative (NR) household samples, and two others (Colombia, Mexico) were based on nationally representative household samples in urbanized areas. The
Israeli survey is a representative sample of individuals.
cThe response rate was calculated as the ratio of the number of households in which an interview was completed to the number of households originally
sampled, excluding from the denominator households known not to be eligible either because they were vacant at the time of initial contact or because the
residents were unable to speak the designated languages of the survey. The weighted average response rate for all countries included was 71.7%.
dBrazil, Israel and South Africa did not have an age-restricted part II sample. All other countries, with the exception of India and Ukraine (which were age-
restricted to ≤ 39 years) were age-restricted to ≤ 44 tears.
eThe New Zealand response rate was calculated on the entire survey sample size which was of respondents age 16+ years, giving a total of 12,992. For purposes
of this analysis we only used respondents aged 18+ years.
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countries (t = 7.5, P < 0.001) (Table 2). Among the high-
income countries, the ratio ranged from ≤ 30% in France,
Germany, Italy and the Netherlands to > 40% in the USA
and Israel. Among the low- to middle-income countries,
the lowest ratios were in Colombia (46.7%) and South
Africa (49.6%), and the highest (57-58%) in Brazil, China
and Ukraine. Consistent with these results, the 30-day pre-
valence of MDE was somewhat lower in high-income
Table 2 Prevalence (%) of DSM-IV/CIDI major depressive episodes in the 18 countries participating in the WMH
surveys a
Screen
positive, mean
± SE
Lifetime
prevalence, mean
± SE
Lifetime/
Screen positive,
± mean ± SE
12-month
prevalence, mean
± SE
12-month/
Screen
positive, mean
± SE
12-month/
lifetime,
mean ± SE
Age of onset,
median (IQR)b
I. High-income
Belgium 49.4 ± 2.5 14.1 ± 1.0 28.5 ± 1.9 5.0 ± 0.5 10.0 ± 1.0 35.2(2.8 29.4
(20.9 to 41.3)
France 65.0 ± 1.7 21.0 ± 1.1 32.3 ± 1.4 5.9 ± 0.6 9.0 ± 0.9 27.9(2.6 28.4
(19.3 to 38.9)
Germany 43.1 ± 1.4 9.9 ± 0.6 23.0 ± 1.3 3.0 ± 0.3 6.9 ± 0.6 30.1 ± 2.1 27.6
(18.6 to 39.6)
Israel 45.1 ± 0.8 10.2 ± 0.5 22.6 ± 1.0 6.1 ± 0.4 13.5 ± 0.8 59.6 ± 2.3 25.5
(18.1 to 38.5)
Italy 44.9 ± 1.7 9.9 ± 0.5 22.1 ± 1.0 3.0 ± 0.2 6.7 ± 0.5 30.2 ± 1.9 27.7
(19.1 to 39.1)
Japan 29.9 ± 0.8 6.6 ± 0.5 22.2 ± 1.4 2.2 ± 0.4 7.4 ± 1.2 33.3 ± 4.2 30.1
(20.8 to 45.3)
Netherlands 53.2 ± 1.6 17.9 ± 1.0 33.6 ± 1.8 4.9 ± 0.5 9.2 ± 1.0 27.3 ± 2.6 27.2
(19.3 to 39.5)
New Zealand 61.9 ± 0.6 17.8 ± 0.4 28.7 ± 0.6 6.6 ± 0.3 10.6 ± 0.5 37.0 ± 1.5 24.2
(16.1 to 34.5)c
Spain 37.7 ± 1.0 10.6 ± 0.5 28.2 ± 1.2 4.0 ± 0.3 10.6 ± 0.8 37.5 ± 1.9 30.0
(19.7 to 44.3)
United States 62.0 ± 0.9 19.2 ± 0.5 30.9 ± 0.7 8.3 ± 0.3 13.3 ± 0.5 43.1 ± 1.2 22.7
(15.1 to 34.6)
Total 52.3 ± 0.4 14.6 ± 0.2 28.1 ± 0.3 5.5 ± 0.1 10.6 ± 0.2 37.7 ± 0.7 25.7
(17.3 to 37.2)
II. Low- to
middle-
income
Sao Pâulo,
Brazil
66.0 ± 1.0 18.4 ± 0.8 27.9 ± 1.1 10.4 ± 0.6 15.8 ± 0.8 56.7 ± 1.5 24.3
(17.2 to 35.8)
Colombia 58.6 ± 1.1 13.3 ± 0.6 22.6 ± 1.0 6.2 ± 0.4 10.6 ± 0.7 46.7 ± 2.6 23.5
(15.6 to 33.6)
Pondicherry,
India
25.0 ± 0.9 9.0 ± 0.5 35.9 ± 1.5 4.5 ± 0.4 18.0 ± 1.4 50.0 ± 3.0 31.9
(24.5 to 42.7)
Lebanon 57.7 ± 1.8 10.9 ± 0.9 18.9 ± 1.3 5.5 ± 0.7 9.5 ± 1.2 50.0 ± 3.7 23.8
(17.5 to 32.8)
Mexico 40.6 ± 1.1 8.0 ± 0.5 19.6 ± 1.2 4.0 ± 0.3 9.8 ± 0.8 50.0 ± 2.7 23.5
(16.7 to 34.0)
Shenzen, China 54.6 ± 0.9 6.5 ± 0.4 12.0 ± 0.7 3.8 ± 0.3 6.9 ± 0.5 58.0 ± 2.6 18.8
(14.9 to 23.4)
South Africa 56.1 ± 1.3 9.8 ± 0.7 17.4 ± 1.2 4.9 ± 0.4 8.6 ± 0.8 49.6 ± 2.7 22.3
(15.8 to 33.8)
Ukraine 82.4 ± 1.1 14.6 ± 0.7 17.7 ± 0.8 8.4 ± 0.6 10.2 ± 0.7 57.8 ± 2.2 27.8
(18.7 to 39.6)
Total 54.1 ± 0.4 11.1 ± 0.2 19.8 ± 0.4 5.9 ± 0.2 10.5 ± 0.3 53.3 ± 0.9 24.0
(17.0 to 34.8)
aAssessed in part I sample. Prevalence for the pooled samples (developed and developing) include respondents ages 18+. Prevalence for individual countries are
assessed for the total sample in the country.
bIQR, interquartile range.
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(mean ± SE 1.8% ± 0.1%) than in low- to middle-income
(2.6 ± 0.1%) countries.
The last column of Table 2 shows that the median
retrospectively reported age of onset (AOO) was similar
for high-income and low- to middle-income countries
(25.7 vs. 24.0, respectively) and that the interquartile
ranges were largely overlapping. The 95% confidence
intervals indicate that across all countries, the risk per-
iod for onset of depression ranges from the mid-late
adolescence to the early 40s. In high-income countries,
the earliest median AOO estimates occurred in the USA
(22.7) and New Zealand (24.2), whereas the latest were
in Spain (30.0) and Japan (30.1). In low- to middle-
income countries, the earliest median AOO estimates
were in China (18.8) and South Africa (22.3), and the
latest in Ukraine (27.8) and India (31.9).
Impairment
As expected, MDE was associated with substantial
impairment in the WMH data. Moreover, the degree of
impairment increased progressively with recency of
MDE. (Table 3) This was true in both high and low- to
middle-income countries, apart from Japan, in which
the impairment level was exceptionally low. We note
that the non-MDE comparison group, which has the
lowest level of impairment, comprised not only healthy
respondents but also respondents with other DSM-IV
diagnoses (Table 3).
For respondents with current MDE, the mean level of
impairment was between approximately five (high-
income) and eight (low- to middle-income) times as
high as for respondents without MDE, with differences
in mean scores of 12.3 (15.3 minus 3.0) in high-income
countries and 8.8 (10.1 minus 1.3) in low- to middle-
income countries. To put these differences into perspec-
tive, the mean differences in all high-income countries
combined (15.3-3.0 = 12.3) and in all low- to middle-
income countries combined (10.1-1.3 = 8.9) were both
equal to 1.4 standard deviations on the impairment
scale in those countries. Effect sizes such as these are
Table 3 Comparisons of functional impairment (WHO-DAS Global Scores)a by recency of DSM-IV/CIDI major depressive
episodes in the 18 countries participating in the WMH surveys
Past 30 days Past 12 monthsb > 12 months ago No lifetime MDE
Mean ± SE n Mean ± SE n Mean ± SE n Mean ± SE n SDc F
I. High-income
Belgium 11.3 ± 3.3+ 42 7.5 ± 2.1+ 71 3.5 ± 0.5 254 3.2 ± 0.7 676 8.4 3.2*
France 13.6 ± 2.6+ 38 6.6 ± 1.1 + 134 4.0 ± 0.5 476 3.2 ± 0.4 788 8.4 7.9*
Germany 15.3 ± 5.4+ 36 4.1 ± 1.0 73 2.4 ± 0.4 263 2.7 ± 0.3 951 7.9 2.8
Israel 21.5 ± 2.4+ 82 9.7 ± 1.0+ 208 6.8 ± 0.8+ 211 5.0 ± 0.2 4358 12.0 24.7*
Italy 15.4 ± 2.5+ 58 6.3 ± 2.0+ 71 3.0 ± 0.4+ 323 2.1 ± 0.2 1327 6.8 13.5*
Japan 2.9 ± 2.6 11 2.9 ± 0.8+ 49 1.5 ± 0.2 125 1.0 ± 0.2 882 4.4 2.3
Netherlands 17.9 ± 2.4+ 42 5.7 ± 1.1 93 5.1 ± 0.4 341 4.1 ± 0.5 618 8.8 12.5*
New Zealand 11.7 ± 1.0+ 292 5.0 ± 0.5+ 606 3.2 ± 0.2+ 1473 2.5 ± 0.1 5064 7.6 32.9*
Spain 15.7 ± 2.2+ 109 6.1 ± 1.0+ 138 4.3 ± 0.6+ 425 2.1 ± 0.2 1449 7.6 24.9*
United States 15.8 ± 1.2+ 297 7.6 ± 0.6+ 496 4.3 ± 0.2+ 1002 3.0 ± 0.2 3896 9.0 54.9*
Total 15.3 ± 0.7+ 1005 6.8 ± 0.3+ 1942 3.9 ± 0.1+ 4903 3.0 ± 0.1 20,096 8.9 149.4*
II. Low- to middle-incomed
Sao Pâulo, Brazil 12.9 ± 1.6+ 260 6.8 ± 0.6+ 280 4.1 ± 0.5+ 413 1.8 ± 0.2 1989 7.8 44.0*
Colombia 5.1 ± 1.4+ 82 3.3 ± 0.7+ 194 1.8 ± 0.3+ 316 0.9 ± 0.1 1789 4.2 11.1*
Pondicherry, India 2.3 ± 0.5+ 71 3.2 ± 0.8+ 83 1.5 ± 0.4 153 1.0 ± 0.1 1066 4.3 3.9*
Lebanon 9.3 ± 1.5+ 72 3.7 ± 0.8+ 71 3.4 ± 0.7+ 162 1.5 ± 0.2 726 5.8 17.3*
Mexico 8.0 ± 1.8+ 117 3.4 ± 0.7+ 142 1.4 ± 0.3+ 250 0.6 ± 0.1 1853 4.3 8.5*
Shenzen, China 3.3 ± 0.5+ 101 1.7 ± 0.4+ 144 0.6 ± 0.1 138 0.5 ± 0.0 2093 2.4 16.9*
Ukraine 14.8 ± 1.2+ 229 10.91.1+ 159 6.8 ± 1.1+ 238 3.7 ± 0.3 1093 9.7 46.3*
Total 10.1 ± 0.7+ 932 5.2 ± 0.3+ 1073 3.1 ± 0.2+ 1670 1.3 ± 0.1 10,608 6.1 112.6*
*Significantly different at the .05 level based on a 3 degree of freedom test
+Significantly different from respondents with no lifetime MDE at the +.05 level, 2-sided test
aWHO-DAS: World Health Organization-Disability Assessment Schedule
bExcludes respondents with MDE in the past 30 days
cSD: Standard deviation of the impairment score in the total sample
dData for South Africa are not available.
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large [25]. The biggest differences (greater than seven-
fold) are in Italy, Spain, Brazil and Mexico and the smal-
lest (less than fivefold) in Belgium, Israel, India and
Ukraine. Respondents with MDE in the past year (but
not currently) reported impairment scores between
approximately twofold (high-income) and fourfold (low-
to middle-income) that of the non-MDE group,
although this difference was not significant in Germany
or the Netherlands. The largest mean differences
(greater than threefold) were in low- to middle-income
countries (Mexico, Brazil, Colombia, India and China),
and the smallest (approximately twofold) in four high-
income countries (France, Belgium, Israel, New Zeal-
and). In seven countries, (five high-income and two low-
to middle-income), there was no significant difference in
impairment between respondents with MDE prior to the
past year and the non-MDE subsample. In five countries
(Spain, Brazil, Colombia, Lebanon and Mexico), the
MDE positive group had an approximately twofold
higher level of impairment than the non-MDE group.
The association between prevalence and impairment
As noted in the introduction, a previous cross-national
WHO study carried out in primary-care waiting-room
samples found that depressed respondents in countries
in which the prevalence of depression was estimated to
be highest reported the lowest average levels of impair-
ment associated with their depression, whereas the high-
est impairment was reported by depressed respondents
in countries in which the prevalence of depression was
estimated to be lowest [15]. We investigated this issue
in the WMH data by creating a small data file in which
each survey was treated as a separate observation, and
the variables were the measures of prevalence (reported
in Table 2) and a measure of impairment associated
with MDE (based on the results reported in Table 3).
However, the impairment scores differed from those in
Table 3 in that they represented the difference in mean
impairment scores of respondents with 12-month MDE
compared with those with no lifetime history of MDE in
the survey. This difference was taken to represent the
effect of recent MDE as assessed by the CIDI on impair-
ment in the survey.
Unlike the earlier primary-care study, we found that
the association between prevalence and impairment was
positive. (Table 4 Table 5) This was true not only in the
total sample of all countries (r = 0.48) but also when we
looked separately at high-income (r = 0.34) and low- to
middle-income (r = 0.80) countries. In addition, when
we deconstructed these associations into correlations of
impairment with the two components of prevalence (the
percentage of respondents endorsing an MDE stem
question and the conditional prevalence estimate of
MDE of screen-positives), we found that the first
correlation was considerably stronger than the second in
both the total sample of countries (r = 0.45, 0.11) and in
low- to middle-income countries (r = 0.76, 0.04),
whereas the first correlation was stronger than the sec-
ond in high-income countries (r = 0.17, 0.45).
Sociodemographic factors
Tables 4 and 5 show the bivariate associations of the
sociodemographic characteristics with 12-month MDE
(tables showing the country-specific distributions of the
demographic variables and 12-month prevalences of
MDE are available upon request). Consistent with pre-
vious epidemiologic studies, women were on average
twice as likely as men to be classified as having MDE.
This difference was significant in 15 of the eighteen
countries, and even in the three exceptions (Belgium,
Germany and China), women had higher rates than
men. In the developed countries, the significant odds
ratios ranged from 1.6 in Israel to 2.7 in Spain, and in
the developing countries, they ranged from 1.9 in India
and Colombia to 2.6 in Brazil. The association between
gender and MDE did not differ significantly between
high-income and low- to middle-income countries (c21
= 2.3, P = 0.13).
The associations between age group and MDE varied
considerably between countries. In two high-income and
five low- to middle-income countries, there were no sig-
nificant associations. In six high-income countries and
in Brazil, respondents in the youngest age group (18 to
34) were 3 to 5.5 times as likely to have MDE as those
in the oldest age group (65+), but in India and Ukraine,
young age was associated with low risk. The 35 to 49
year age group was also at increased risk for MDE, espe-
cially in New Zealand (OR = 4.4), the USA (OR = 3.9)
and Brazil (OR = 3.3); in Ukraine, however, they had a
significantly lower risk than those in the oldest age
group. Mid-life (ages 50 to 64), encompasses a period of
transition from work to retirement in many countries.
Compared with respondents age 65+, participants in
this group had an increased risk of MDE in eight high-
income countries and Brazil, with ORs ranging from 1.6
(Spain) to 3.1 (USA). Overall, the association between
age and MDE was significantly stronger in high-income
than low- to middle-income countries (c23 = 67.1, p <
.001).
Marital status was a consistently significant correlate
of MDE. Being separated was associated with increased
risk of MDE in twelve countries, with odds ratios vary-
ing from < 4.0 in five countries to > 8.0 in India (OR =
8.2), Japan (OR = 10.8) and Lebanon (OR = 19.3). Being
divorced was associated with MDE in seven of the ten
developed and four of the eight developing countries,
with unusually high ORs in Japan (OR = 5.1), China
(OR = 6.2) and Ukraine (OR = 4.2). Being widowed was
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Table 4 Associations of demographic characteristics with 12-month DSM-IV/CIDI major depressive episode in high-income countries (bivariate analyses)a
Parameter Total, OR
(95% CI)
Belgium, OR
(95% CI)
France, OR
(95% CI)
Germany, OR
(95% CI)
Israel, OR
(95% CI)
Italy, OR
(95% CI)
Japan, OR
(95% CI)
Netherlands, OR
(95% CI)
New Zealand, OR
(95% CI)
Spain, OR
(95% CI)
USA, OR
(95% CI)
Gender
Women 1.8
(1.6 to 2.0)*
1.6
(0.9 to 2.8)
1.7
(1.2 to 2.5)*
1.7
(1.0 to 3.0)
1.6
(1.2 to 2.1)*
2.5
(1.6 to 3.8)*
2.3
(1.4 to 4.0)*
2.3
(1.5 to 3.5)*
1.7
(1.4 to 2.1)*
2.7
(1.9 to 3.8)*
1.7
(1.4 to 2.1)*
Men 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Age
18-34 2.7
(2.3 to 3.1)*
2.6
(0.9 to 7.7)
3.5
(1.7 to 7.4)*
3.8
(1.6 to 9.2)*
1.1
(0.7 to 1.6)
0.8
(0.5 to 1.5)
4.8
(2.3 to 10.0)*
2.6
(1.2 to 5.7)*
5.5
(3.9 to 7.8)*
1.0
(0.6 to 1.7)
4.3
(3.1 to 6.0)*
35-49 2.2
(1.9 to 2.6)*
2.2
(1.0 to 4.8)*
2.5
(1.2 to 5.3)*
2.3
(1.0 to 5.5)
1.0
(0.6 to 1.4)
0.7
(0.4 to 1.3)
2.7
(1.3 to 5.6)*
2.5
(1.2 to 5.4)*
4.4
(3.2 to 6.2)*
1.1
(0.7 to 1.6)
3.9
(2.7 to 5.5)*
50-64 2.0
(1.7 to 2.3)*
2.5
(1.1 to 5.6)*
2.3
(1.1 to 4.7)*
2.4
(1.0 to 5.5)*
1.0
(0.7 to 1.6)
1.2
(0.7 to 2.1)
2.4
(1.2 to 4.8)*
1.9
(0.9 to 3.8)*
2.9
(2.0 to 4.1)*
1.6
(1.1 to 2.3)*
3.1
(2.1 to 4.5)*
65+ 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Marital
statusb
Separated 3.6
(2.9 to 4.6)*
7.3
(1.8 to 29.7)*
6.2
(1.8 to 21.3)*
- 2.6
(1.0 to 6.8)
2.8
(1.1 to 7.5)*
10.8
(2.1 to 55.6)*
- 3.4
(2.4 to 4.8)*
3.2
(1.3 to 7.7)*
4.0
(2.7 to 6.0)*
Divorced 2.1
(1.8 to 2.5)*
1.9
(0.7 to 5.3)
1.1
(0.5 to 2.5)
3.1
(1.4 to 7.1)*
2.2
(1.5 to 3.4)*
0.6
(0.1 to 5.0)
5.1
(2.1 to 12.6)*
2.7
(1.5 to 4.9)*
2.8
(2.0 to 3.8)*
3.3
(1.2 to 8.9)*
1.7
(1.3 to 2.3)*
Widowed 1.4
(1.2 to 1.7)*
1.4
(0.6 to 3.4)
1.5
(0.7 to 3.2)
2.3
(1.2 to 4.5)*
2.1
(1.4 to 3.3)*
1.5
(0.9 to 2.7)
0.9
(0.4 to 2.1)
0.8
(0.3 to 2.2)
1.3
(0.9 to 1.8)
1.4
(0.9 to 2.2)
1.2
(0.8 to 1.9)
Never
married
1.8
(1.6 to 2.0)*
1.3
(0.6 to 2.9)
2.0
(1.2 to 3.5)*
2.6
(1.6 to 4.2)*
1.4
(1.0 to 1.9)*
1.5
(1.0 to 2.2)
3.1
(1.6 to 5.7)*
1.8
(1.0 to 3.4)
2.3
(1.8 to 3.0)*
0.9
(0.6 to 1.4)
1.8
(1.5 to 2.1)*
Currently
married
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Living arrangements
Alone 1.8
(1.6 to 2.0)*
1.3
(0.6 to 2.7)
1.4
(0.9 to 2.3)
2.5
(1.6 to 3.9)*
2.1
(1.5 to 2.9)*
1.7
(1.1 to 2.8)*
2.9
(1.2 to 6.8)*
1.6
(1.1 to 2.4)*
1.8
(1.4 to 2.3)*
1.0
(0.7 to 1.6)
1.7
(1.4 to 2.2)*
With others 1.9
(1.7 to 2.2)*
1.5
(0.8 to 2.8)
2.2
(1.4 to 3.7)*
2.9
(1.6 to 5.1)*
1.6
(1.2 to 2.1)*
1.4
(0.9 to 2.1)
3.0
(1.6 to 5.6)*
1.9
(0.8 to 4.3)
2.5
(2.0 to 3.1)*
1.2
(0.8 to 1.7)
1.8
(1.5 to 2.1)*
With
spouse
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Income
Low 1.7
(1.5 to 2.0)*
1.3
(0.7 to 2.6)
2.4
(1.2 to 4.6)*
2.7
(1.3 to 5.6)*
1.1
(0.7 to 1.7)
1.3
(0.6 to 2.9)
0.5
(0.2 to 1.4)
1.1
(0.6 to 1.9)
2.2
(1.6 to 3.0)*
1.0
(0.5 to 2.0)
2.1
(1.5 to 2.8)*
Low
average
1.3
(1.1 to 1.5)*
1.1
(0.5 to 2.4)
1.4
(0.7 to 2.6)
1.6
(0.7 to 3.5)
0.9
(0.6 to 1.3)
1.2
(0.6 to 2.3)
0.5
(0.2 to 1.2)
0.8
(0.4 to 1.8)
1.5
(1.2 to 2.0)*
1.1
(0.7 to 1.8)
1.4
(1.0 to 1.8)*
High
average
1.1
(0.9 to 1.2)
0.9
(0.4 to 2.0)
1.3
(0.7 to 2.3)
1.6
(0.9 to 3.1)
0.8
(0.6 to 1.1)
0.9
(0.5 to 1.5)
0.5
(0.2 to 1.3)
0.8
(0.5 to 1.6)
1.3
(1.0 to 1.7)
1.0
(0.6 to 1.5)
1.1
(0.8 to 1.5)
High 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Education
Low 1.0
(0.9 to 1.2)
1.4
(0.8 to 2.5)
- 1.0
(0.2 to 4.3)
1.5
(1.0 to 2.2)*
1.5
(0.9 to 2.5)
0.2
(0.1 to 0.6)*
1.1
(0.6 to 1.9)
0.9
(0.7 to 1.2)
1.2
(0.7 to 1.9)
1.4
(1.1 to 1.8)*
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Table 4 Associations of demographic characteristics with 12-month DSM-IV/CIDI major depressive episode in high-income countries (bivariate analyses)a
(Continued)
Low
average
1.1
(1.0 to 1.3)
0.9
(0.4 to 2.2)
- 1.6
(0.4 to 5.8)
1.3
(0.9 to 1.8)
0.8
(0.4 to 1.4)
0.7
(0.4 to 1.4)
1.3
(0.7 to 2.6)
1.1
(0.8 to 1.4)
0.8
(0.5 to 1.3)
1.2
(0.9 to 1.5)
High
average
1.1
(0.9 to 1.3)
1.8
(0.8 to 3.8)
- 1.1
(0.2 to 5.2)
1.0
(0.7 to 1.6)
0.9
(0.5 to 1.5)
0.7
(0.3 to 1.6)
1.5
(0.7 to 3.2)
0.9
(0.7 to 1.1)
1.0
(0.7 to 1.6)
1.4
(1.0 to 1.8)*
High 1.0 1.0 - 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
*Significant at the 0.05 level, two-sided test.
aAll models were bivariate models with the sociodemographic factors as predictors and 12-month MDE as the response variable. The models for total
(first column) control for countries. The models for income were estimated in part II samples, whereas all other models were estimated in part I samples.
bIn some countries, people were categorized as separated/widowed/divorced because they were known to have married previously but not any longer, but the specific category was unknown. These cases were
dropped from the model using marriage as the predictor. Specifically, there was one such case in Japan, two cases in the USA, one case in New Zealand, and ninety-one in the ESEMeD countries
(France, Germany, Italy, Netherlands, Spain, Belgium).
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Table 5 Associations of demographic characteristics with 12-month DSM-IV/CIDI major depressive episode in low- to middle-income countries: bivariate
analyses)a
Total, OR (95%
CI)
Brazil, OR (95%
CI)
Colombia, OR
(95% CI)
India, OR (95%
CI)
Lebanon, OR
(95% CI)
Mexico, OR (95%
CI)
China, OR (95%
CI)
South Africa, OR
(95% CI)
Ukraine, OR
(95% CI)
Gender
Women 2.1 (1.8 to 2.3)* 2.6 (1.9 to 3.5)* 1.9 (1.4 to 2.7)* 1.9 (1.3 to 2.7)* 2.1 (1.3 to 3.4)* 2.1 (1.5 to 2.9)* 1.2 (0.8 to 1.7) 2.2 (1.5 to 3.2)* 2.5 (2.0 to 3.0)*
Men 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Age
18-34 0.9 (0.8 to 1.1) 3.0 (1.6 to 5.7)* 4.9 (0.9 to 28.3) 0.4 (0.2 to 1.0)* 1.7 (0.8 to 3.7) 0.4 (0.2 to 1.2) 2.8 (0.8 to 9.4) 1.3 (0.6 to 2.6) 0.4 (0.3 to 0.6)*
35-49 1.0 (0.8 to 1.2) 3.3 (1.7 to 6.5)* 3.9 (0.7 to 23.1) 1.2 (0.6 to 2.5) 2.2 (1.0 to 5.2) 0.5 (0.2 to 1.3) 1.6 (0.5 to 5.3) 1.6 (0.8 to 3.2) 0.5 (0.3 to 0.7)*
50-64 1.0 (0.8 to 1.3) 2.5 (1.4 to 4.5)* 3.4 (0.6 to 20.1) 1.5 (0.7 to 3.2) 1.9 (0.9 to 4.1) 0.5 (0.2 to 1.5) 0.8 (0.2 to 3.3) 1.7 (0.8 to 3.6) 0.7 (0.5 to 1.1)
65+ 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Marital
statusb
Separated 1.7 (1.3 to 2.2)* 1.6 (1.1 to 2.3)* 0.9 (0.6 to 1.6) 8.2 (2.2 to 30.6)* 19.3 (5.0 to 74.4)* 1.9 (1.0 to 3.6)* - 2.7 (0.7 to 9.6) 6.6 (1.1 to 38.0)*
Divorced 3.0 (2.4 to 3.9)* 3.0 (1.9 to 4.9)* 1.2 (0.3 to 4.3) - 0.8 (0.2 to 4.2) 1.2 (0.4 to 3.8) 6.2 (2.2 to 17.3)* 2.1 (1.3 to 3.5)* 4.2 (2.9 to 6.2)*
Widowed 2.7 (2.2 to 3.2)* 1.1 (0.7 to 1.9) 1.6 (0.9 to 2.9) 2.2 (1.5 to 3.2)* 1.4 (0.6 to 3.6) 2.7 (1.5 to 5.0)* 4.1 (0.8 to 20.7) 2.3 (1.3 to 4.0)* 8.0 (5.3 to 12.0)*
Never married 1.0 (0.9 to 1.1) 1.0 (0.7 to 1.3) 1.3 (0.9 to 1.8) 0.3 (0.1 to 0.6)* 1.3 (0.8 to 2.0) 0.8 (0.5 to 1.3) 1.4 (1.0 to 1.9) 0.7 (0.5 to 1.0)* 0.8 (0.5 to 1.3)
Currently
married
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Living arrangements
Alone 1.6 (1.4 to 1.9)* 1.3 (0.8 to 2.0) 0.6 (0.3 to 1.2) 1.2 (0.6 to 2.5) 1.3 (0.7 to 2.5) 1.0 (0.5 to 1.9) 1.6 (1.1 to 2.3)* 1.2 (0.8 to 1.9) 2.5 (1.9 to 3.3)*
With others 1.2 (1.1 to 1.3)* 1.2 (1.0 to 1.5) 1.3 (0.9 to 1.8) 0.6 (0.4 to 0.9)* 1.4 (0.8 to 2.2) 1.1 (0.8 to 1.6) 0.9 (0.4 to 2.1) 0.9 (0.6 to 1.2) 1.5 (1.1 to 2.0)*
With spouse 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Income
Low 1.1 (0.9 to 1.3) 1.0 (0.7 to 1.5) 1.4 (0.8 to 2.3) 1.7 (0.9 to 3.2) 1.0 (0.5 to 2.3) 2.1 (1.4 to 3.2)* 0.7 (0.4 to 1.2) 0.9 (0.6 to 1.4) 0.7 (0.4 to 1.3)
Low average 1.1 (0.9 to 1.3) 1.1 (0.8 to 1.6) 1.5 (0.9 to 2.5) 2.1 (1.2 to 3.8)* 1.1 (0.5 to 2.5) 1.5 (1.0 to 2.3) 0.6 (0.3 to 1.0) 0.9 (0.5 to 1.4) 0.8 (0.4 to 1.4)
High average 1.0 (0.8 to 1.2) 1.2 (0.8 to 1.8) 0.8 (0.5 to 1.3) 2.0 (1.2 to 3.5)* 1.3 (0.6 to 2.7) 1.4 (0.8 to 2.2) 0.5 (0.3 to 0.8)* 0.5 (0.3 to 1.2) 0.9 (0.5 to 1.7)
High 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
Education
Low 1.1 (1.0 to 1.4) 0.7 (0.5 to 1.1) 0.9 (0.6 to 1.4) 14.1 (3.4 to 58.9)
*
1.2 (0.7 to 2.1) 2.1 (1.3 to 3.2)* 0.2 (0.1 to 0.6)* 0.5 (0.2 to 1.5) 2.3 (1.4 to 3.8)*
Low average 1.1 (0.9 to 1.3) 1.1 (0.8 to 1.6) 1.2 (0.7 to 1.9) 1.0 (0.1 to 12.5) 1.2 (0.6 to 2.4) 1.6 (1.0 to 2.5) 0.5 (0.3 to 0.7)* 2.1 (1.1 to 4.1)* 1.3 (0.9 to 1.8)
High average 0.9 (0.8 to 1.1) 0.9 (0.7 to 1.2) 0.9 (0.5 to 1.5) 3.9 (0.6 to 27.0) 1.3 (0.7 to 2.4) 1.2 (0.7 to 1.9) 0.8 (0.5 to 1.2) 1.0 (0.5 to 1.9) 1.0 (0.6 to 1.5)
High 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0
*Significant at the 0.05 level, two-sided t-test
aAll models were bivariate models with the sociodemographic factors as predictors and 12-month MDE as the response variable. The models for total (first column) control for countries. The models for income were
estimated in part II samples, whereas all other models were estimated in part I samples.
bIn some countries, people were categorized as separated/widowed/divorced because they were known to have married previously but not anymore, but the specific category was unknown. These cases were
dropped from the model using marriage as the predictor. There were 48 cases in India, 35 in Brazil, 664 in Ukraine and 1 case in South Africa.
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less consistently and more modestly associated with
MDE with the exception of Ukraine, where widows
were eight times as likely as married men and women
to have MDE. In the high-income countries, there was a
significantly increased OR of MDE among the never
married. However, India and South Africa were the only
two low- to middle-income samples with significant
ORs, and in these countries never being married was
associated with low risk. Overall, the association
between marital status and MDE differed significantly
between high and low- to middle-income countries (c23
= 124.4, P < 0.001), due to stronger associations of
being separated and never married with depression in
high-income countries, and stronger associations of
being divorced and widowed with depression in low- to
middle-income countries. In contrast to marital status,
living arrangements per se were more modestly asso-
ciated with MDE. This association was significant in
eight of the high-income countries and in Ukraine and
China, with the overall difference in the association
between high and low- to middle-income countries sig-
nificant (c22 = 39.0, P < 0.001) due to a higher OR
between being unmarried but living with others in high
than in low- to middle-income countries.
The poorest respondents in France, Germany, New
Zealand and the USA had an approximately twofold
increased odds of MDE compared with those in the
highest income group. In the low- to middle-income
countries, in comparison, income was not significantly
related to MDE. This stronger association between
income and MDE in higher-income countries was signif-
icant overall (c23 = 19.3, P < 0.001). Similarly, among
the non-Asian countries, low education was significantly
associated with MDE only in Israel, the USA, Mexico
and Ukraine. The findings for the Asian countries were
more complex. In India, respondents with the lowest
education were 14 times as likely to have MDE as those
with the highest education. In Japan and China, the
reverse pattern was found, with the least educated hav-
ing the lowest risk of MDE. The association between
education and MDE overall did not differ significantly
between high and low- to middle-income countries (c23
= 6.2, P = 0.10).
Discussion
Consistent with previous cross-national reports, the
WMH MDE prevalence estimates varied considerably
between countries, with the highest prevalence estimates
found in some of the wealthiest countries in the world.
However, contrary to our initial expectation, we found
no evidence that this wide cross-national variation was
due as much to cross-national differences in endorsing
diagnostic stem questions as to conditional prevalence
of MDE among respondents who endorsed a diagnostic
stem. The ratio of the highest to lowest screen-positive
rates across countries (3.3) was very similar to the ratio
of the highest to lowest conditional prevalence rates
among screen-positives (3.0). As expected, we also
found that MDE was associated with substantial impair-
ment. However, contrary to our initial expectation, we
did not find that cross-national differences in prevalence
estimates were inversely related to differences in average
level of impairment associated with depression; indeed,
the opposite pattern was found.
Taken together, these results argue against the sugges-
tion that the wide cross-national variation in depression
prevalence estimates in the WMH surveys and previous
epidemiologic studies is due to the threshold for defin-
ing clinically significant depression in standard diagnos-
tic interviews differing across countries. If that were the
case, we would expect that the cases of depression
detected in countries with the lowest estimated preva-
lence of depression would be the most severe cases,
resulting in high impairment rates among these cases,
whereas the opposite would be true in countries with
the highest estimated prevalence of depression. Further-
more, we would expect that reports of core depressive
symptoms would be more similar across countries than
estimates of disorder prevalence. Neither of these expec-
tations was borne out in the WMH data. A question
can be raised by our results regarding why the associa-
tions between prevalence and impairment were so dif-
ferent from those reported in the earlier WHO study
[15]; however, it is important to bear in mind that this
earlier study was based on primary-care samples, for
which selection bias regarding seeking help on the basis
of either distress or impairment might induce a more
negative association between these two variables than
exists in the population. The WMH surveys, by contrast,
are based on general population samples, for which the
selection bias issues that occur in treatment samples do
not arise.
Although these results add indirect support to a sub-
stantive interpretation of the cross-national differences
in MDE found here, they shed no light on why these
differences exist. Differences in stress exposure, in reac-
tivity to stress, and in endogenous depression unrelated
to environmental provoking factors are all possibilities.
On one level, it seems counterintuitive that people in
high-income countries should experience more stress
than those in low- to middle-income countries. How-
ever, it has been suggested that depression is to some
extent an illness of affluence [26]. A related argument is
that income inequality, which is for the most part
greater in high than low- to middle-income countries,
promotes a wide variety of chronic conditions that
includes depression [27]. Further analyses of the WMH
data might be able to shed some light on these
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perspectives; however such an analysis was beyond the
scope of the current report, which focused on the eva-
luation of a more methodological interpretation of the
observed cross-national differences in depression preva-
lence estimates.
In considering a substantive interpretation of our find-
ings, it is noteworthy that although lifetime prevalence
estimates were found to be significantly higher in high
than low- to middle-income countries overall, no signifi-
cant difference in 12-month prevalence was found. The
ratio of 12-month to lifetime prevalence estimates,
furthermore, was significantly higher in low- to middle-
income than in high-income countries. It might be that
these results reflect genuinely lower lifetime prevalence
but higher persistence of depression in low- to middle-
income than high-income countries, but another plausi-
ble and more parsimonious explanation is that error in
recall of previous lifetime episodes is higher in low- to
middle-income than high-income countries. Longitudi-
nal data collection would be required to document such
a difference rigorously [28,29]. Although such data do
not exist in all WMH series, it is important to recognize
this possibility of cross-national variation in recall error
before launching an extensive investigation of substan-
tive explanations. It might be that a fruitful focus of
subsequent WMH analysis would be on the youngest
respondents, where lifetime recall error might be least
pronounced. Alternatively, it might be that the investiga-
tion of cross-national differences in lifetime prevalence
should be abandoned in favor of a focus on recent pre-
valence in recognition of the plausibility of significant
cross-national variation in recall error of lifetime
prevalence.
Another implication of the methodological limitation
of the WMH surveys being all cross-sectional is that it
made it impossible to determine the temporal direction
of the associations examined between depression and
the sociodemographic variables. This means that even
though variables such as education and marital status
were considered predictors of depression, they might
actually have been consequences or involved in recipro-
cal causal relationships with depression. However,
within the context of that limitation, the sociodemo-
graphic patterns reported here are broadly consistent
with those found in previous community epidemiologic
surveys of depression [2,5,7,9,13], adding to confidence
in the generalizability of the WMH finding.
The results reported here have several other limita-
tions, relating more generally to the WMH findings
[30]. Some of the most important of these issues involve
sampling. The response rates varied widely. Although
the response rates did not appear to be related to
depression prevalence, it is possible that in some set-
tings, particularly those where treatment is unavailable,
the most depressed people were unable to participate.
Some surveys only included metropolitan areas, whereas
others involved national samples. This too may have
affected estimates of cross-national variation in preva-
lence. In addition, the surveys did not include institutio-
nalized patients, people in jails and prisons, people in
the military, people who were too intoxicated to be
interviewed, or people with severe cognitive or physical
disabilities. The samples also reflected survivor bias,
which could be of considerable importance for under-
standing differences between high-income and low- to
middle-income countries, given the gap in life expec-
tancy of 10 to 15 years between people in developed
and developing countries [31]. Thus, the rates reported
here provide conservative estimates of MDE prevalence.
A final noteworthy sample bias is that South Africa was
the only African country included in this report [32]
even though the WMH survey was also conducted in
Nigeria [33]. Nigeria was excluded because of the extre-
mely low prevalence of MDE (3.1% lifetime; 1.1% 12-
month) and other disorders. These low prevalence esti-
mates raise questions about the willingness of respon-
dents in the Nigerian survey to disclose symptoms to
strangers or lay interviewers, and the appropriateness of
the CIDI structure for that setting [34]. They also
reduced our statistical power to examine the associa-
tions of depression considered in the Nigerian data. A
similar experience may have occurred in another African
population-based survey using the CIDI that was not
part of the WMH series. That survey, carried out in
Addis Ababa, also found low rates of affective disorders
[35]. Given the high level of exposure to trauma in
extremely poor countries such as these [36], research is
urgently needed to determine the best approaches to
study the prevalence of mental disorders in these
settings.
The measure of MDE also had inherent limitations.
The structure of the CIDI, including the choice of stem
questions in the screening section, may have led to
underestimates of depression in some settings. As noted
above in the section on measurement, the interview
translation, back-translation and harmonization process
in the WMH surveys included customization within
countries of the terms used to describe the core symp-
toms of depression (that is, sadness, depression, loss of
interest) based on clinical experiences of local collabora-
tors and the results of pilot studies [19]. However, no
attempt was made to develop distinct cut-off points in
the CIDI diagnostic algorithms for different countries or
to go beyond the DSM-IV criteria to develop distinct
criteria for different countries that might have increased
our ability to detect depression or depression-equiva-
lents. It is noteworthy that in the countries for which
we carried out blinded clinical reappraisal interviews
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with subsamples of WMH respondents, we found no
evidence for systematic bias in the diagnostic threshold
for depression [18], but clinical reappraisal interviews
were not carried out in all WMH countries, and it is
conceivable that such studies would have found sys-
tematic differences in the ability of the CIDI to detect
clinical depression across countries.
Despite these limitations, the WMH data provide use-
ful new information about the epidemiology of MDE. We
found wide variation not only in the prevalence of MDE
but also in the proportion of people who endorsed diag-
nostic stem questions for MDE, a pattern that has seldom
been examined in previous epidemiologic studies [37].
We found cross-national consistency, by contrast, in the
impairment associated with MDE. This association has to
our knowledge never been considered previously in
cross-national community epidemiologic surveys. Our
results confirm the public-health importance of major
depression as a commonly occurring and seriously
impairing condition with a generally early AOO and per-
sistent course in a wide range of countries. In addition,
we replicated previous findings on the sociodemographic
correlates of MDE. We also documented an intriguing
opposite-sign pattern of differences between high and
low- to middle-income countries in estimates of lifetime
prevalence and persistence of MDE, which might be due
to differences in recall error. Future research on cross-
national differences in depression needs to take this pat-
tern into consideration, and to develop a workable strat-
egy to deal with the possibility of differential recall error
as a plausible contributor to cross-national differences in
prevalence estimates.
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